Phase 3
Completed N=321
A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)
Source: ClinicalTrials.gov NCT02741245 ↗Enrolled (actual)
321
Serious AEs
0.3%
Results posted
Mar 2018
Primary outcomePrimary: Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) — -18.7; -39.8; -47.2; -54.6 Percentage Change — p=<0.001
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study will evaluate the efficacy and safety and tolerability of 2 dose levels of MK-0653H in Japanese participants. The primary hypotheses are that the administration of MK-0653H is safe and tolerable and that MK-0653H is superior to single entity of Ezetimibe and Rosuvastatin in percent reduction from baseline in low-density lipoprotein-cholesterol (LDL-C) after 12 weeks of treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) |
-18.7; -39.8; -47.2; -54.6; -60.5 | <0.001 sig |
| PRIMARY Percentage of Participants Who Experience at Least 1 Adverse Event (AE) |
31.4; 34.7; 42.3; 40.8; 37.5 | — |
| PRIMARY Percentage of Participants Who Had Study Drug Discontinued Due to Adverse Event |
0.0; 0.0; 0.0; 2.8; 1.4 | — |
| PRIMARY Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs |
0.0; 6.9; 4.2; 8.5; 2.8 | — |
| PRIMARY Percentage of Participants Who Experience 1 or More Gallbladder-related AEs |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs |
0.0; 1.4; 4.2; 2.8; 2.8 | — |
| PRIMARY Percentage of Participants Who Experience 1 or More Hepatitis-related AEs |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Normal Limit (ULN) |
0.0; 0.0; 0.0; 1.4; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN) |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN) |
0.0; 0.0; 0.0; 1.4; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥5 Times Upper Normal Limit (ULN) |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥5 Times Upper Normal Limit (ULN) |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥10 Times Upper Normal Limit (ULN) |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN) |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN) |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants With Potential Hy's Law Condition |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
| PRIMARY Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms |
0.0; 0.0; 0.0; 0.0; 0.0 | — |
Eligibility Criteria
Inclusion Criteria
- Japanese
- Outpatient with hypercholesterolemia
- Female participant who is of reproductive potential has to agree to remain abstinent or use (or partner use) two acceptable methods of birth control from date of signed informed consent to the 14 days after the last dose of study drug
- Will maintain a stable diet that is consistent with the Japan Atherosclerosis Society Guideline 2012 (JAS 2012) for prevention of atherosclerotic cardiovascular diseases for the duration of the study
Exclusion Criteria
- Uncontrolled hypertension (treated or untreated)
- Uncontrolled type 1 or type 2 diabetes mellitus
- History of coronary artery disease (CAD), CAD-equivalent disease
- Familial hypercholesterolemia or has undergone LDL apheresis
- Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins
- Has had a gastrointestinal tract bypass, or other significant intestinal malabsorption
- History of cancer within the past 5 years (except for successfully treated dermatological basal cell or squamous cell carcinoma or in situ cervical cancer)
- Human Immunodeficiency Virus (HIV) positive
- History of drug/ alcohol abuse within the past 5 years or psychiatric illness not adequately controlled and stable on pharmacotherapy
- Consumes more than 25 g of alcohol per day
- Currently following an excessive weight reduction diet
- Currently engages in a vigorous exercise regimen (e.g.; marathon training, body building training etc.) or intends to start training during the study
- Hypersensitivity or intolerance to Ezetimibe or Rosuvastatin
- Myopathy or rhabdomyolysis with Ezetimibe or any statin
- Pregnant or lactating
- Taking any other investigational drugs and/or has taken any investigational drugs within 30 days
Data sourced from ClinicalTrials.gov (NCT02741245). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.